This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The number of soft tissue filler injections performed by aesthetic injectors has continued to increase over the last few years. To provide a high standard of safety and achieve individualized, reproducible, and long-lasting outcomes, aesthetic injectors must have a solid foundation in anatomy, facial biomechanics, rheology, and injection biomechanics. Adverse events associated with soft tissue filler injections can be severe, especially if the aesthetic injector unintentionally injects the soft tissue filler into the patient's arterial vascular circulation and the administered product reaches the arterial bloodstream. Although the face has a rich arterial vascular supply that may seem overwhelmingly complex, it can be broken down systematically according to its internal and external vascular territories. To provide guidance for aesthetic practitioners performing minimally invasive facial injections for aesthetic purposes, this narrative article will discuss the course, depth, and branching pattern of the facial arteries based on the most frequently injected anatomical regions. In this article, we focus on vascular safe zones rather than danger zones.
This study confirms that the regionally relevant practice of CT-based 3D-optimised planning results in improved tumour dose coverage compared with traditional points-based planning methods and also improves dose to the rectum and bladder.
deterioration, and 16 (16%) stability in EF values compared to the baseline. Age (50 vs >50), menopausal status, tobacco use, history of DM and HT, multiple medication use, tumor location, stage, HRT use, presence of axilla and MI in the RT field, RT technique, median heart dose (5 Gy vs >5 Gy), V10 (10% vs >10%), V20 (3% vs >3%) and V30 (1% vs >1%) were not effective on the variation in EF in both the first and last controls. When the patients with right-and left-sided tumors were compared; although the median heart dose and the number of patients receiving RT to the MI region were higher in patients with leftsided tumors, EF values in the first and last controls were similar to the patients with right-sided tumors. Conclusion: We observed that concurrent use of trastuzumab with RT did not increase the risk of cardiac toxicity. Therefore, trastuzumab can be used safely in patients with breast cancer who will undergo adjuvant RT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.